Sublocade: Information for Pharmacists
*UPDATED NOVEMBER 2024 The content in this article has been adapted from resources originally published by the British Columbia Centre on Substance Use and PharmaCare. These resources are included at the end of this article. As resources are continually being updated, please refer to the most up-to-date guidance, if applicable. |
Some patients in BC are being prescribed buprenorphine extended-release injection for the treatment of moderate-to-severe opioid use disorder (OUD).
DRUG NAME | Buprenorphine (Sublocade™) | ||
---|---|---|---|
INDICATION | Opioid Use Disorder | ||
DIN | 02483084 | STRENGTH AND FORM | 100mg/0.5mL subcutaneous injection |
02483092 | 300mg/1.5mL subcutaneous injection | ||
PHARMACARE COVERAGE | Plan Z, B, C and G |
Sublocade is an extended-release formulation of buprenorphine that is administered monthly via abdominal subcutaneous injection for the management of moderate to severe opioid use disorder.
Sublocade is associated with significantly higher treatment retention and mean abstinence percentages (over 40%) in individuals with moderate to severe opioid use disorder.
Information for Pharmacists
Dispensing Sublocade
Sublocade may be prescribed by a physician, nurse practitioner or Registered Nurse/Registered Psychiatric Nurse Opioid Use Disorder Certified (RN/RPN CP-OUD) who has completed the manufacturer’s training course.
Sublocade must be administered by a physician, nurse (NP, RN/RPN, LPN) or an injection certified pharmacist. Pharmacists are strongly encouraged to complete UBC’s Continuing Pharmacy Professional Development - Practical Administration of Sublocade Injection course as well as the manufacturer’s training course prior to ordering, dispensing or administering Sublocade.
As the formulation carries significant risks to the patient if not administered correctly, Sublocade must never be dispensed directly to the patient.
Given the unique dispensing pathway necessary for Sublocade, prescribers and pharmacists should create a plan in advance for each prescription.
Examples of information to include in plans includes:
- What day the prescription will be dispensed and picked up
- Who will pick-up the prescription
- If the perscription is being delivered, what is the delivery address
- Any additional information necessary to meet College requirements
Pharmacists must also provide adequate counselling at the time of dispensing each prescription in accordance with the College’s counselling requirements.
If not being administered by a pharmacist, Sublocade is to be either picked up by a nurse or prescriber on behalf of the patient, or delivered to the clinic, keeping in mind proper storage and delivery of the prescription.
Storage of Sublocade in Community Pharmacies
Sublocade must be safely and securely stored and maintained following appropriate cold chain management.
While the College’s current narcotic storage bylaws do not include provisions for the refrigeration of Schedule 1A drugs, community pharmacies are expected to take additional care to ensure appropriate security, storage and refrigeration of Sublocade. This includes:
- Not ordering more of the drug than is necessary;
- Implementing additional security procedures if needed; and
- Ensuring narcotic record-keeping requirements are met, including but not limited to:
- Maintenance of a perpetual inventory
- Physical inventory counts
- Reconciliation
- Documentation
With a Schedule 1A drug that requires refrigeration beginning to be used by patients in BC, the College will be reviewing related requirements on narcotics storage and proposing updates as needed. For now, community pharmacists are expected to use their professional judgement to ensure appropriate security and storage of Sublocade, keeping in mind that the drug needs to be refrigerated.
Additional Resources
- October 2024: BCCSU Extended-release Burprenorphine Bulletin
- October 2024: DECISION SUPPORT TOOL – For Registered Nurse/Registered Psychiatric Nurse Opioid Use Disorder Certified Prescribing of Buprenorphine/naloxone and Extended-release Buprenorphine
- Pharmacare Newsletter - November 2024
- Sublocade – Product Monograph